Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: RJMC who wrote (3796)	1/10/2001 2:14:30 AM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

Bob, I agree in general, but I think their could be substantial news between now and May. Several partnerships are in discussion, no telling what will come to fruition. The approval of the IND and start of the Phase I/II Trial for N901-DM1. The conclusion of the Single Dose Trial and Milestone Payment for completing it. Possible Milestones from the agreements with DNA and/or ABGX, probably for the conjugation of new drugs and initiation of preclinical trials. No doubt there are others, but perhaps the biggest thing that could happen would be meeting the rumored milestone for 50% tumor shrinkage. Numerous knowledgeable and credible posters believe this milestone exists, no one knows the criteria, but if the conditions are met before May, efficacy will be established before Dr. Schilsky's presentation. This should not detract from his presentation, it should actually enhance it as most everyone at the conference will know that the drug's working, they'll want to attend his presentation to learn just how well. I believe the price will stabilize and gradually return to prior highs as more becomes known, but I also believe the Biotech Sector will also become favored again in time. For now we're moving with the sector and lack of anticipated news. Gary